No Data
Express News | RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $25 Price Target
Apellis Pharmaceuticals Analyst Ratings
Evercore Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Earnings Preview: APLS to Report Financial Results Pre-market on November 05
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating
Axonis Therapeutics Announces $115 Million Series A Financing